Episode Summary
Executive Summary: This AMA preview centers on aging science and the evidence behind three widely discussed geroprotective molecules: NAD and its precursors NR/NMN, rapamycin, and metformin. The hosts and guest Matt Kaeberlein emphasize the difficulty of measuring biological aging, the promise and limits of biomarkers and epigenetic clocks, and the need to compare these compounds against stronger evidence standards before drawing clinical conclusions.
Main Topics: Why compare NAD, rapamycin, and metformin (Priority: 5/5): The episode frames these three molecules as the most frequently asked-about geroprotective candidates and argues they should be evaluated side by side to understand the strength and limitations of the evidence for each. Biomarkers of aging: what they are and what they can do (Priority: 5/5): The discussion contrasts aging research with fields like lipidology, where ApoB is a clear biomarker, and argues that aging still lacks a similarly definitive, predictive marker for individual health outcomes. Functional measures vs molecular clocks (Priority: 5/5): The speakers favor practical functional outcomes such as VO2 max, strength, muscle mass, and metabolic markers as more clinically meaningful than relying solely on epigenetic or commercial aging clocks. Epigenetic clocks and their limitations (Priority: 5/5): Matt explains how methylation-based clocks estimate chronological age and may correlate with future risk, but notes major concerns about validation, individual-level accuracy, and commercialization. Model systems in aging research (Priority: 4/5): The episode previews a broader discussion of how aging is studied across yeast, worms, flies, mice, dogs, and humans, highlighting the tradeoffs between experimental control and relevance to human aging. NAD and its precursors as the main focus (Priority: 5/5): The conversation signals that most of the episode will dive deeply into NAD, NR, and NMN, including the nuances and unanswered questions surrounding their role in aging and healthspan. Skepticism about commercial aging tests and interventions (Priority: 4/5): The speakers criticize companies that sell biological age tests and then pair them with supplements or interventions, warning that this can amount to moving the goalposts or even snake oil.
Key Arguments: Aging research lacks a biomarker as clean and actionable as ApoB is for lipidology, making interpretation of interventions much harder. A useful aging biomarker should predict future health outcomes at the individual or population level, not just correlate with age. Short-term intervention readouts may reflect rate of aging or even reversal of aging, and may not be the same as markers of biological age. Functional improvements in organs and tissues may be more trustworthy than epigenetic clocks for judging whether an intervention is beneficial. Epigenetic clocks can estimate chronological age well, but their ability to predict meaningful future outcomes remains incompletely proven. Commercial aging clocks are concerning because they may overstate certainty and encourage unsupported supplement sales. Comparing NAD-related compounds with rapamycin and metformin helps contextualize how much evidence exists for each class of geroprotectors. The field needs definitive validation studies, especially in mice, to show whether clocks track lifespan or healthspan changes. Existing biomarkers may already contain useful predictive information, but the field has not yet identified the best combination or algorithm. Clinical practice already relies on functional and phenotypic markers, which may be the most practical current proxies for biological aging.
Data Points: AMA episode number: 35 - This is introduced as Ask Me Anything episode 35. Previous guest appearances by Matt Kaeberlein: 2 prior appearances - Peter notes that Matt has been on the podcast twice before, most recently in September of the previous year. Number of geroprotective molecules emphasized: 3 - The episode focuses on NAD/NR/NMN, rapamycin, and metformin. Approximate number of epigenetic clocks: about two dozen - Matt says there are roughly two dozen epigenetic clocks in circulation. Epigenetic age prediction accuracy: within plus or minus five years - The clocks can predict chronological age with fairly high accuracy. Caloric restriction example: 70% of weight-maintenance caloric intake - Peter uses a hypothetical three-month caloric restriction intervention to illustrate the kind of biomarker readout he would want. Longitudinal human follow-up example: 20 years later - Matt references studies where people were followed for two decades to assess whether epigenetic age predicted later outcomes. Mouse validation experiment timing: 20 months old at baseline; 6 months later re-measurement - Matt proposes a definitive mouse study design to test whether epigenetic clocks predict lifespan and intervention response. Commercialization timeline concern: last 3 decades - Matt notes that the human environment has changed dramatically over the last three decades, complicating biomarker relevance.
Pivotal Quotes: "What I think you really want is something you can measure that is predictive at either the individual or the population level of future health outcomes." — Matt Kaeberlein: Defines the standard he believes a true biomarker of biological aging should meet. "I think the evidence in support of that comes mostly from longitudinal studies in humans... they have a lower likelihood of developing specific diseases or potentially of dying." — Matt Kaeberlein: Explains the main argument for epigenetic clocks as predictors of future risk. "It's just frankly dishonest." — Matt Kaeberlein: His critique of companies selling biological age tests and claiming precise measurement and reversal of aging.
Implications: Listeners should treat aging biomarkers and commercial clocks cautiously and prioritize functional health measures while the field works toward better validation. The episode sets up a rigorous comparison of NAD, rapamycin, and metformin against the current evidence base rather than hype.
About Peter Attia Drive
Expert insight on health, performance, longevity, critical thinking, and pursuing excellence. Dr. Peter Attia (Stanford/Hopkins/NIH-trained MD) talks with leaders in their fields.